BS
Insider
Brian C Stephenson
Secretary, Treasurer & CFOBrian C Stephenson (Secretary, Treasurer & CFO) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in BridgeBio Pharma, Inc. (BBIO). Across 3 priced purchase filings, the average 21-session return was +19.4% from execution and +15.7% from disclosure (delay-adjusted; derived). The largest single filing was $209K of FTH (8,655 sh across 2 lots, as filed), executed Jun 30.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+19.4%
avg across 3 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+15.7%
same 3 filings, from disclosure
Filings, ttm
3
3 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$479K
shares × price, as filed
Last traded
Jul 1
Filed Jul 1
Median ADV $3.7M across their filed names
Open performance→Volume by month
Buys $479K
Sells $2.9M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
BBIORecent filings
FTHPURCHASE
Faeth Therapeutics, Inc.
View filing →
$209K8,655 sh across 2 lots
Exec Jun 30
Filed Jul 1 · 8:09 PM ET FTHPURCHASE Faeth Therapeutics, Inc. View filing → $105K
4,212 sh × $24.90
Exec Jun 26
Filed Jun 26 · 7:40 PM ET FTHPURCHASE Faeth Therapeutics, Inc. View filing → $165K
6,836 sh × $24.12
Exec Jun 23
Filed Jun 24 · 6:58 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $279K
8,400 sh × $33.18
Exec Feb 25 2025
Filed Feb 27 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $150K
4,148 sh × $36.16
Exec Feb 19 2025
Filed Feb 19 2025 · 5:30 PM ET BBIOSALE BridgeBio Pharma, Inc. View filing → $2.5M
68,000 sh × $36.29
Exec Jan 28 2025
Filed Jan 30 2025 · 5:30 PM ET